Quest Diagnostics Q1 2025 10-Q Filed
Ticker: DGX · Form: 10-Q · Filed: 2025-04-23T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
Quest Diagnostics Q1 2025 10-Q is in. Financials for Jan-Mar 2025 vs 2024 detailed.
AI Summary
Quest Diagnostics Inc. filed its 10-Q for the period ending March 31, 2025. The filing includes financial data for the first quarter of 2025, comparing it to the same period in 2024. Specific financial statement line items and balance sheet accounts are detailed, such as common stock, retained earnings, and accumulated other comprehensive income.
Why It Matters
This filing provides investors with the latest financial performance and position of Quest Diagnostics, crucial for understanding the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Latest financial data available)
- 2025-04-23 — Filing Date (When the report was submitted to the SEC)
- 2025-01-01 to 2025-03-31 — Q1 2025 Period (First quarter financial performance)
- 2024-01-01 to 2024-03-31 — Q1 2024 Period (Comparative first quarter financial performance)
Key Players & Entities
- Quest Diagnostics Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250423 (date) — Filing date
- 2025-01-01 (date) — Start of Q1 2025
- 2024-01-01 (date) — Start of Q1 2024
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on April 23, 2025.
What fiscal year end does Quest Diagnostics report?
Quest Diagnostics reports a fiscal year end of December 31.
What are some of the balance sheet accounts detailed in the filing?
The filing details accounts such as Common Stock, Additional Paid-In Capital, Retained Earnings, Accumulated Other Comprehensive Income, Treasury Stock, and Noncontrolling Interest.
What periods are being compared in this filing?
This filing compares financial data for the period January 1, 2025, to March 31, 2025, with the period January 1, 2024, to March 31, 2024.
From the Filing
0001022079-25-000120.txt : 20250423 0001022079-25-000120.hdr.sgml : 20250423 20250423162136 ACCESSION NUMBER: 0001022079-25-000120 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250423 DATE AS OF CHANGE: 20250423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QUEST DIAGNOSTICS INC CENTRAL INDEX KEY: 0001022079 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 161387862 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12215 FILM NUMBER: 25861786 BUSINESS ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 BUSINESS PHONE: 9735202700 MAIL ADDRESS: STREET 1: 500 PLAZA DRIVE CITY: SECAUCUS STATE: NJ ZIP: 07094 FORMER COMPANY: FORMER CONFORMED NAME: CORNING CLINICAL LABORATORIES INC DATE OF NAME CHANGE: 19960903 10-Q 1 dgx-20250331.htm 10-Q dgx-20250331 0001022079 12/31 2025 Q1 FALSE 277 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:CAD dgx:claim 0001022079 2025-01-01 2025-03-31 0001022079 2025-04-15 0001022079 2024-01-01 2024-03-31 0001022079 2025-03-31 0001022079 2024-12-31 0001022079 2023-12-31 0001022079 2024-03-31 0001022079 us-gaap:CommonStockMember 2024-12-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001022079 us-gaap:RetainedEarningsMember 2024-12-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001022079 us-gaap:TreasuryStockCommonMember 2024-12-31 0001022079 us-gaap:NoncontrollingInterestMember 2024-12-31 0001022079 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001022079 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001022079 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001022079 us-gaap:CommonStockMember 2025-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001022079 us-gaap:RetainedEarningsMember 2025-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001022079 us-gaap:TreasuryStockCommonMember 2025-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2025-03-31 0001022079 us-gaap:CommonStockMember 2023-12-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001022079 us-gaap:RetainedEarningsMember 2023-12-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001022079 us-gaap:TreasuryStockCommonMember 2023-12-31 0001022079 us-gaap:NoncontrollingInterestMember 2023-12-31 0001022079 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001022079 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001022079 us-gaap:CommonStockMember 2024-03-31 0001022079 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001022079 us-gaap:RetainedEarningsMember 2024-03-31 0001022079 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001022079 us-gaap:TreasuryStockCommonMember 2024-03-31 0001022079 us-gaap:NoncontrollingInterestMember 2024-03-31 0001022079 dgx:InvigorateProgramMember 2025-03-31 0001022079 dgx:InvigorateProgramMember 2025-01-01 2025-03-31 0001022079 dgx:InvigorateProgramMember 2024-01-01 2024-03-31 0001022079 us-gaap:CostOfSalesMember dgx:InvigorateProgramMember 2025-01-01 2025-03-31 0001022079 us-gaap:SellingGeneralAndAdministrativeExpensesMember dgx:InvigorateProgramMember 2025-01-01 2025-03-31 0001022079 us-gaap:CostOfSalesMember dgx:InvigorateProgramMember 2024-01-01 2024-03-31 0001022079 us-gaap:SellingGeneralAndAdministrativeExpensesMember dgx:InvigorateProgr